Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan
· Delayed Price · Currency is TWD 18.15
-0.15 (-0.82%)
Apr 29, 2026, 1:30 PM CST
Welgene Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 375.94 | 322.55 | 280.55 | 321.9 | 312.65 | Upgrade
|
| Revenue Growth (YoY) | 16.55% | 14.97% | -12.85% | 2.96% | -21.46% | Upgrade
|
| Cost of Revenue | 219.76 | 186.71 | 160.83 | 180.1 | 179.38 | Upgrade
|
| Gross Profit | 156.18 | 135.84 | 119.72 | 141.8 | 133.27 | Upgrade
|
| Selling, General & Admin | 129.61 | 110.69 | 100.43 | 104.3 | 97.13 | Upgrade
|
| Research & Development | 26.51 | 25.85 | 24.15 | 21.63 | 21.64 | Upgrade
|
| Operating Expenses | 156.05 | 136.69 | 123.98 | 124.52 | 118.97 | Upgrade
|
| Operating Income | 0.13 | -0.85 | -4.26 | 17.29 | 14.3 | Upgrade
|
| Interest Expense | -3.41 | -2.97 | -2.62 | -0.28 | -0.43 | Upgrade
|
| Interest & Investment Income | 2.16 | 1.46 | 1.46 | 0.51 | 0.17 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -2.89 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.25 | 0.01 | -0.02 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.46 | 3 | 1.69 | 0.25 | 0.18 | Upgrade
|
| EBT Excluding Unusual Items | 1.34 | 0.88 | -3.73 | 17.74 | 11.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -4.19 | 5.04 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.37 | -0.11 | - | 0.21 | Upgrade
|
| Other Unusual Items | - | - | 0.81 | - | - | Upgrade
|
| Pretax Income | 1.34 | 1.25 | -3.03 | 13.55 | 16.6 | Upgrade
|
| Income Tax Expense | 0.04 | 0.54 | 0.11 | 4.01 | 2.89 | Upgrade
|
| Earnings From Continuing Operations | 1.3 | 0.71 | -3.15 | 9.54 | 13.7 | Upgrade
|
| Minority Interest in Earnings | 0.03 | 0.4 | 0.5 | 0.01 | -0 | Upgrade
|
| Net Income | 1.33 | 1.11 | -2.65 | 9.55 | 13.7 | Upgrade
|
| Net Income to Common | 1.33 | 1.11 | -2.65 | 9.55 | 13.7 | Upgrade
|
| Net Income Growth | 20.14% | - | - | -30.29% | -53.98% | Upgrade
|
| Shares Outstanding (Basic) | 22 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | -4.88% | - | -0.10% | 0.93% | 10.99% | Upgrade
|
| EPS (Basic) | 0.06 | 0.05 | -0.11 | 0.41 | 0.59 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.05 | -0.11 | 0.41 | 0.59 | Upgrade
|
| EPS Growth | 26.31% | - | - | -30.53% | -58.74% | Upgrade
|
| Free Cash Flow | -6.08 | 51.27 | -28.1 | 24.57 | 6.87 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | 2.20 | -1.21 | 1.05 | 0.30 | Upgrade
|
| Dividend Per Share | - | - | - | 0.180 | 0.480 | Upgrade
|
| Dividend Growth | - | - | - | -62.50% | -56.44% | Upgrade
|
| Gross Margin | 41.54% | 42.11% | 42.67% | 44.05% | 42.63% | Upgrade
|
| Operating Margin | 0.03% | -0.27% | -1.52% | 5.37% | 4.57% | Upgrade
|
| Profit Margin | 0.35% | 0.34% | -0.94% | 2.97% | 4.38% | Upgrade
|
| Free Cash Flow Margin | -1.62% | 15.90% | -10.02% | 7.63% | 2.20% | Upgrade
|
| EBITDA | 27.92 | 14.54 | 9.48 | 24.44 | 22.23 | Upgrade
|
| EBITDA Margin | 7.43% | 4.51% | 3.38% | 7.59% | 7.11% | Upgrade
|
| D&A For EBITDA | 27.79 | 15.39 | 13.74 | 7.15 | 7.93 | Upgrade
|
| EBIT | 0.13 | -0.85 | -4.26 | 17.29 | 14.3 | Upgrade
|
| EBIT Margin | 0.03% | -0.27% | -1.52% | 5.37% | 4.57% | Upgrade
|
| Effective Tax Rate | 3.14% | 43.52% | - | 29.58% | 17.43% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.